Themis Medicare Ltd
Themis Medicare is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.[1]
- Market Cap ₹ 1,992 Cr.
- Current Price ₹ 216
- High / Low ₹ 266 / 131
- Stock P/E 71.9
- Book Value ₹ 32.2
- Dividend Yield 0.23 %
- ROCE 19.6 %
- ROE 16.5 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 36.0% CAGR over last 5 years
Cons
- Debtor days have increased from 122 to 150 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
138 | 148 | 172 | 167 | 203 | 217 | 210 | 184 | 202 | 231 | 395 | 354 | 364 | |
156 | 139 | 153 | 156 | 171 | 184 | 184 | 182 | 166 | 181 | 299 | 287 | 311 | |
Operating Profit | -18 | 9 | 19 | 11 | 31 | 33 | 26 | 3 | 36 | 50 | 96 | 67 | 53 |
OPM % | -13% | 6% | 11% | 7% | 15% | 15% | 12% | 1% | 18% | 22% | 24% | 19% | 14% |
2 | 3 | 4 | 12 | 3 | 3 | 3 | 3 | 3 | 4 | 7 | 12 | 7 | |
Interest | 13 | 15 | 16 | 14 | 12 | 12 | 12 | 12 | 13 | 13 | 9 | 10 | 10 |
Depreciation | 5 | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | 12 |
Profit before tax | -35 | -9 | 1 | 2 | 15 | 16 | 9 | -15 | 18 | 32 | 84 | 59 | 37 |
Tax % | 0% | 5% | -34% | -30% | -4% | 10% | 1% | 13% | 12% | 17% | 27% | 26% | |
-35 | -8 | 2 | 2 | 15 | 15 | 9 | -13 | 16 | 27 | 62 | 43 | 28 | |
EPS in Rs | -4.31 | -1.01 | 0.18 | 0.24 | 1.77 | 1.64 | 1.01 | -1.38 | 1.73 | 2.90 | 6.69 | 4.71 | 3.02 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 10% | 15% | 7% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 21% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | 22% |
5 Years: | 36% |
3 Years: | 40% |
TTM: | -38% |
Stock Price CAGR | |
---|---|
10 Years: | 41% |
5 Years: | 50% |
3 Years: | 82% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 14% |
3 Years: | 20% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
Reserves | 44 | 36 | 40 | 40 | 56 | 133 | 147 | 134 | 150 | 177 | 234 | 273 | 287 |
121 | 124 | 115 | 109 | 95 | 82 | 80 | 82 | 100 | 87 | 80 | 92 | 95 | |
65 | 58 | 67 | 67 | 61 | 54 | 56 | 74 | 67 | 65 | 61 | 82 | 90 | |
Total Liabilities | 238 | 225 | 231 | 225 | 220 | 278 | 292 | 299 | 326 | 338 | 384 | 456 | 481 |
104 | 94 | 91 | 92 | 89 | 124 | 126 | 123 | 116 | 133 | 144 | 162 | 166 | |
CWIP | 7 | 10 | 11 | 3 | 5 | 9 | 2 | 2 | 8 | 2 | 3 | 3 | 3 |
Investments | 7 | 10 | 10 | 11 | 11 | 12 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
120 | 111 | 119 | 119 | 115 | 133 | 153 | 162 | 191 | 192 | 226 | 280 | 301 | |
Total Assets | 238 | 225 | 231 | 225 | 220 | 278 | 292 | 299 | 326 | 338 | 384 | 456 | 481 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-14 | -3 | 8 | 11 | 19 | -2 | 8 | 11 | 0 | 57 | 34 | 16 | |
-7 | -1 | -3 | -2 | -4 | -4 | -0 | -4 | -5 | -16 | -16 | -24 | |
-1 | 28 | 2 | -15 | -13 | 5 | -9 | -10 | 7 | -26 | -18 | 0 | |
Net Cash Flow | -21 | 24 | 8 | -6 | 2 | -0 | -1 | -3 | 2 | 16 | 1 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 114 | 65 | 71 | 88 | 73 | 81 | 120 | 145 | 186 | 123 | 93 | 150 |
Inventory Days | 150 | 237 | 231 | 223 | 210 | 250 | 253 | 284 | 313 | 273 | 150 | 213 |
Days Payable | 223 | 247 | 250 | 272 | 152 | 163 | 156 | 186 | 171 | 144 | 79 | 123 |
Cash Conversion Cycle | 41 | 55 | 52 | 38 | 131 | 168 | 217 | 243 | 328 | 253 | 165 | 239 |
Working Capital Days | 96 | 77 | 63 | 68 | 53 | 74 | 132 | 134 | 178 | 154 | 125 | 177 |
ROCE % | -12% | 4% | 10% | 10% | 17% | 15% | 9% | -1% | 13% | 17% | 31% | 20% |
Documents
Announcements
- Compliance Certificate Under Regulation 40 (9) Of The SEBI (LODR) Regulations, 2015 16 Apr
- Compliance Certificate Under Regulation 7(3) Of The SEBI (LODR) Regulations, 2015, For The Financial Year Ended 31St March, 2024 10 Apr
- Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 8 Apr
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 8 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Feb 2023Transcript PPT REC
-
Nov 2022Transcript PPT
Product Portfolio
The company manufactures and markets bulk APIs of synthetic and biotech origin, bulk intermediates, and formulations. In the formulations segment, the company manufactures anti-TB, anti-malarial, anti-cholesterol, and pain management drugs. [1]
The company manufactures 190+ different drugs for ~20 different therapeutic areas. [2]